GenomOncology and OHSU Knight Lab Join Forces to Enhance Patient Access to Oncology Trials
GenomOncology (GO), a prominent leader in precision medicine reporting solutions, has recently declared a significant strategic alliance with the Knight Diagnostics Lab (KDL) at Oregon Health & Science University (OHSU). This collaboration is set to revolutionize how cancer patients are matched with applicable clinical trials, thus facilitating quicker access to cutting-edge treatment options.
The primary focus of this partnership is the implementation of GO's Clinical Trials Matching Solution at KDL, designed to enhance the matching process for cancer clinical trials. The integration of this solution directly within KDL's decision support framework allows for the automatic identification of relevant clinical trials based on patients' molecular profiles and clinical histories, ensuring a more personalized approach to patient care.
The Clinical Trials Matching Solution stands out for its comprehensiveness, offering essential trial information including phase, title, locations, sponsor details, and eligibility criteria. This not only educates the healthcare providers but also empowers them with transparent insights into why particular trials are matched to specific patients, considering trial arms and patient clinical statuses. Such transparency aids pathologists and multidisciplinary teams in making well-informed recommendations.
Garreth Hippe, Chief Commercial Officer of GenomOncology, emphasized the critical nature of this collaboration. 'Access to clinical trials remains a significant barrier in cancer care,' he remarked. 'Our partnership with OHSU's Knight Diagnostics Lab demonstrates how intelligent automation can break down these barriers. By embedding clinical trial matching directly into the diagnostic workflow, we're ensuring that every patient receives personalized trial options when it matters most.'
Traditional methods for clinical trial matching are often labor-intensive and can lead to oversights, potentially delaying patient enrollment or even missing out on appropriate trials. The automative capabilities of GO's Clinical Trials Matching Solution streamline this usually convoluted process into a user-friendly experience. With rapid, accurate matches, pathologists can now validate and collaborate on trial options quickly, drastically reducing typical waiting times from hours or days to mere minutes. Moreover, KDL pathologists will gain access to clinical trial information through their familiar user interface, a transition that the partnership plans to achieve in a matter of weeks.
Dr. Brian Druker, CEO of the OHSU Knight Cancer Institute, shared his enthusiasm regarding this technological enhancement. 'Our mission is to arm clinicians and patients with actionable, comprehensive information to navigate treatment decisions effectively. GenomOncology's Clinical Trials Matching Solution strengthens our capacity to connect patients with groundbreaking therapeutic options precisely when they are needed most. Our pathologists can now add greater value in every report produced.'
This agreement signifies a notable leap in the realm of precision medicine. It merges sophisticated molecular diagnostics with intelligent clinical trial matching tactics—creating an approach that is not only innovative but also firmly anchored in patient-centered care practices.
In summary, the launch of this partnership provides a significant advancement in how patients facing serious illnesses can access vital clinical trials, ensuring they are matched more efficiently and effectively with treatments that could potentially enhance or save their lives. GenomOncology is devoted to transforming complex clinical and molecular data into actionable insights, assisting in optimizing clinical trials for cancer treatment. For more information, you can visit GenomOncology's website and learn about the Knight Diagnostics Lab by visiting OHSU's page here.
The primary focus of this partnership is the implementation of GO's Clinical Trials Matching Solution at KDL, designed to enhance the matching process for cancer clinical trials. The integration of this solution directly within KDL's decision support framework allows for the automatic identification of relevant clinical trials based on patients' molecular profiles and clinical histories, ensuring a more personalized approach to patient care.
The Clinical Trials Matching Solution stands out for its comprehensiveness, offering essential trial information including phase, title, locations, sponsor details, and eligibility criteria. This not only educates the healthcare providers but also empowers them with transparent insights into why particular trials are matched to specific patients, considering trial arms and patient clinical statuses. Such transparency aids pathologists and multidisciplinary teams in making well-informed recommendations.
Garreth Hippe, Chief Commercial Officer of GenomOncology, emphasized the critical nature of this collaboration. 'Access to clinical trials remains a significant barrier in cancer care,' he remarked. 'Our partnership with OHSU's Knight Diagnostics Lab demonstrates how intelligent automation can break down these barriers. By embedding clinical trial matching directly into the diagnostic workflow, we're ensuring that every patient receives personalized trial options when it matters most.'
Traditional methods for clinical trial matching are often labor-intensive and can lead to oversights, potentially delaying patient enrollment or even missing out on appropriate trials. The automative capabilities of GO's Clinical Trials Matching Solution streamline this usually convoluted process into a user-friendly experience. With rapid, accurate matches, pathologists can now validate and collaborate on trial options quickly, drastically reducing typical waiting times from hours or days to mere minutes. Moreover, KDL pathologists will gain access to clinical trial information through their familiar user interface, a transition that the partnership plans to achieve in a matter of weeks.
Dr. Brian Druker, CEO of the OHSU Knight Cancer Institute, shared his enthusiasm regarding this technological enhancement. 'Our mission is to arm clinicians and patients with actionable, comprehensive information to navigate treatment decisions effectively. GenomOncology's Clinical Trials Matching Solution strengthens our capacity to connect patients with groundbreaking therapeutic options precisely when they are needed most. Our pathologists can now add greater value in every report produced.'
This agreement signifies a notable leap in the realm of precision medicine. It merges sophisticated molecular diagnostics with intelligent clinical trial matching tactics—creating an approach that is not only innovative but also firmly anchored in patient-centered care practices.
In summary, the launch of this partnership provides a significant advancement in how patients facing serious illnesses can access vital clinical trials, ensuring they are matched more efficiently and effectively with treatments that could potentially enhance or save their lives. GenomOncology is devoted to transforming complex clinical and molecular data into actionable insights, assisting in optimizing clinical trials for cancer treatment. For more information, you can visit GenomOncology's website and learn about the Knight Diagnostics Lab by visiting OHSU's page here.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.